Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Cash & Equivalents (2016 - 2025)

Macrogenics (MGNX) has disclosed Cash & Equivalents for 14 consecutive years, with $57.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 68.71% to $57.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.2 million, a 68.71% decrease, with the full-year FY2025 number at $57.2 million, down 68.71% from a year prior.
  • Cash & Equivalents was $57.2 million for Q4 2025 at Macrogenics, down from $80.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $224.3 million in Q1 2023 to a low of $21.5 million in Q2 2022.
  • A 5-year average of $122.4 million and a median of $108.8 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 88.64% in 2022, then surged 406.58% in 2023.
  • Macrogenics' Cash & Equivalents stood at $123.5 million in 2021, then dropped by 11.81% to $108.9 million in 2022, then decreased by 7.28% to $101.0 million in 2023, then surged by 81.11% to $182.8 million in 2024, then tumbled by 68.71% to $57.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Cash & Equivalents are $57.2 million (Q4 2025), $80.1 million (Q3 2025), and $130.7 million (Q2 2025).